FINWIRES · TerminalLIVE
FINWIRES

Tabcorp表示澳洲交易報告和分析中心(Austrac)就洗錢問題展開執法調查;股價暴跌27%。

By

-- 根據週四提交給澳洲證券交易所的文件顯示,Tabcorp Holdings(ASX:TAH)表示,澳洲交易報告和分析中心(Austrac)對其管理洗錢和恐怖主義融資風險的能力提出了「嚴重」擔憂,並已啟動執法調查。 該公司表示,調查初期將重點評估其是否遵守《反洗錢和反恐怖主義融資法》(AML/CTF法案)規定的義務,包括是否擁有合規的AML/CTF計劃、是否有效執行該計劃以及是否對客戶進行適當的監控。 該公司補充道,Austrac表示調查尚處於初期階段,其調查策略將在收集和評估充分證據後確定,所有可能的結果均不排除,包括不採取進一步執法行動的可能性。 Tabcorp董事長Brett Chenoweth表示:“Tabcorp非常重視其反洗錢和反恐融資義務。董事會和管理層將全力配合澳大利亞交易報告和分析中心(Austrac),持續提升Tabcorp的反洗錢/反恐融資風險成熟度。” 該公司股價在上週四的交易中暴跌27%。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661